Literature DB >> 25516641

Alternative splicing of DNA damage response genes and gastrointestinal cancers.

Bahityar Rahmutulla1, Kazuyuki Matsushita1, Fumio Nomura1.   

Abstract

Alternative splicing, which is a common phenomenon in mammalian genomes, is a fundamental process of gene regulation and contributes to great protein diversity. Alternative splicing events not only occur in the normal gene regulation process but are also closely related to certain diseases including cancer. In this review, we briefly demonstrate the concept of alternative splicing and DNA damage and describe the association of alternative splicing and cancer pathogenesis, focusing on the potential relationship of alternative splicing, DNA damage, and gastrointestinal cancers. We will also discuss whether alternative splicing leads to genetic instability, which is considered to be a driving force for tumorigenesis. Better understanding of the role and mechanism of alternative splicing in tumorigenesis may provide new directions for future cancer studies.

Entities:  

Keywords:  Alternative splicing; DNA damage; Gastrointestinal cancer; Genetic instability; Mutation

Mesh:

Substances:

Year:  2014        PMID: 25516641      PMCID: PMC4265588          DOI: 10.3748/wjg.v20.i46.17305

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  98 in total

1.  A genomic view of alternative splicing.

Authors:  Barmak Modrek; Christopher Lee
Journal:  Nat Genet       Date:  2002-01       Impact factor: 38.330

2.  A far upstream element stimulates c-myc expression in undifferentiated leukemia cells.

Authors:  M I Avigan; B Strober; D Levens
Journal:  J Biol Chem       Date:  1990-10-25       Impact factor: 5.157

3.  A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome.

Authors:  Marc Sultan; Marcel H Schulz; Hugues Richard; Alon Magen; Andreas Klingenhoff; Matthias Scherf; Martin Seifert; Tatjana Borodina; Aleksey Soldatov; Dmitri Parkhomchuk; Dominic Schmidt; Sean O'Keeffe; Stefan Haas; Martin Vingron; Hans Lehrach; Marie-Laure Yaspo
Journal:  Science       Date:  2008-07-03       Impact factor: 47.728

4.  Alternative CD44 splicing in intestinal stem cells and tumorigenesis.

Authors:  W Guo; P S Frenette
Journal:  Oncogene       Date:  2013-07-08       Impact factor: 9.867

5.  Human MRE11 is inactivated in mismatch repair-deficient cancers.

Authors:  Giuseppe Giannini; Elisabetta Ristori; Fabio Cerignoli; Christian Rinaldi; Massimo Zani; Alessandra Viel; Laura Ottini; Marco Crescenzi; Stefano Martinotti; Margherita Bignami; Luigi Frati; Isabella Screpanti; Alberto Gulino
Journal:  EMBO Rep       Date:  2002-02-15       Impact factor: 8.807

6.  Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination.

Authors:  Niklas Schultz; Elena Lopez; Nasrollah Saleh-Gohari; Thomas Helleday
Journal:  Nucleic Acids Res       Date:  2003-09-01       Impact factor: 16.971

Review 7.  Gastrointestinal stromal tumor of the stomach: progresses in diagnosis and treatment.

Authors:  K De Vogelaere; M Aerts; P Haentjens; J De Grève; G Delvaux
Journal:  Acta Gastroenterol Belg       Date:  2013-12       Impact factor: 1.316

8.  Overexpression of far upstream element (FUSE) binding protein (FBP)-interacting repressor (FIR) supports growth of hepatocellular carcinoma.

Authors:  Mona Malz; Michael Bovet; Jana Samarin; Uta Rabenhorst; Carsten Sticht; Michaela Bissinger; Stephanie Roessler; Justo Lorenzo Bermejo; Marcus Renner; Diego Francesco Calvisi; Stephan Singer; Matthias Ganzinger; Achim Weber; Norbert Gretz; Martin Zörnig; Peter Schirmacher; Kai Breuhahn
Journal:  Hepatology       Date:  2014-07-31       Impact factor: 17.425

Review 9.  Mechanisms of resistance to therapies targeting BRCA-mutant cancers.

Authors:  Christopher J Lord; Alan Ashworth
Journal:  Nat Med       Date:  2013-10-07       Impact factor: 53.440

10.  c-myc suppressor FBP-interacting repressor for cancer diagnosis and therapy.

Authors:  Kazuyuki Matsushita; Takeshi Tomonaga; Toshiko Kajiwara; Hideaki Shimada; Sakae Itoga; Takaki Hiwasa; Shuji Kubo; Takenori Ochiai; Hisahiro Matsubara; Fumio Nomura
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
View more
  9 in total

1.  Adenovirus-mediated FIR demonstrated TP53-independent cell-killing effect and enhanced antitumor activity of carbon-ion beams.

Authors:  M Kano; K Matsushita; B Rahmutulla; S Yamada; H Shimada; S Kubo; T Hiwasa; H Matsubara; F Nomura
Journal:  Gene Ther       Date:  2015-08-04       Impact factor: 5.250

2.  Haploinsufficiency of the c-myc transcriptional repressor FIR, as a dominant negative-alternative splicing model, promoted p53-dependent T-cell acute lymphoblastic leukemia progression by activating Notch1.

Authors:  Kazuyuki Matsushita; Kouichi Kitamura; Bahityar Rahmutulla; Nobuko Tanaka; Takayuki Ishige; Mamoru Satoh; Tyuji Hoshino; Satoru Miyagi; Takeshi Mori; Sakae Itoga; Hideaki Shimada; Takeshi Tomonaga; Minoru Kito; Yaeko Nakajima-Takagi; Shuji Kubo; Chiaki Nakaseko; Masahiko Hatano; Takashi Miki; Masafumi Matsuo; Masaki Fukuyo; Atsushi Kaneda; Atsushi Iwama; Fumio Nomura
Journal:  Oncotarget       Date:  2015-03-10

Review 3.  Expression of evolutionarily novel genes in tumors.

Authors:  A P Kozlov
Journal:  Infect Agent Cancer       Date:  2016-07-19       Impact factor: 2.965

4.  Disturbed alternative splicing of FIR (PUF60) directed cyclin E overexpression in esophageal cancers.

Authors:  Yukiko Ogura; Tyuji Hoshino; Nobuko Tanaka; Guzhanuer Ailiken; Sohei Kobayashi; Kouichi Kitamura; Bahityar Rahmutulla; Masayuki Kano; Kentarou Murakami; Yasunori Akutsu; Fumio Nomura; Sakae Itoga; Hisahiro Matsubara; Kazuyuki Matsushita
Journal:  Oncotarget       Date:  2018-05-01

Review 5.  Roles of Smads Family and Alternative Splicing Variants of Smad4 in Different Cancers.

Authors:  Irfan Ullah; Weichao Sun; Liling Tang; Jianguo Feng
Journal:  J Cancer       Date:  2018-10-16       Impact factor: 4.207

6.  Genome-Wide Profiling of Prognostic Alternative Splicing Signature in Colorectal Cancer.

Authors:  Zhen Zong; Hui Li; Chenghao Yi; Houqun Ying; Zhengming Zhu; He Wang
Journal:  Front Oncol       Date:  2018-11-20       Impact factor: 6.244

7.  Anti-FIRs (PUF60) auto-antibodies are detected in the sera of early-stage colon cancer patients.

Authors:  Sohei Kobayashi; Tyuji Hoshino; Takaki Hiwasa; Mamoru Satoh; Bahityar Rahmutulla; Sachio Tsuchida; Yuji Komukai; Tomoaki Tanaka; Hisahiro Matsubara; Hideaki Shimada; Fumio Nomura; Kazuyuki Matsushita
Journal:  Oncotarget       Date:  2016-12-13

8.  Pan-cancer analysis of alternative splicing regulator heterogeneous nuclear ribonucleoproteins (hnRNPs) family and their prognostic potential.

Authors:  Hao Li; Jingwei Liu; Shixuan Shen; Di Dai; Shitong Cheng; Xiaolong Dong; Liping Sun; Xiaolin Guo
Journal:  J Cell Mol Med       Date:  2020-09-11       Impact factor: 5.310

9.  A Novel Nomogram Combining Alternative Splicing Events and Clinical Factors for Prognosis Prediction in Head and Neck Squamous Cell Carcinoma.

Authors:  Jun Jiang; Li Niu; Ming-Xia Zhang; Hao Wang; Jia-Qi Xie; Guo-Ping Sun
Journal:  J Oncol       Date:  2022-01-22       Impact factor: 4.375

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.